特立帕肽(PTH(1-34))用于甲状腺切除术后低钙血症的一级预防:THYPOS 试验
这项前瞻性 II 期随机开放标签试验纳入 26 例甲状腺切除术后 4 小时完整 PTH 低于 10 pg/ml 的高危受试者,1:1 随机接受特立帕肽 20 mcg 每 12 小时皮下注射直至出院或标准临床照护。治疗组低钙血症发生率为 3/13,对照组为 11/13(P = .006),相对危险度为 0.26(95%CI 0.09-0.723);住院中位时间治疗组 2 天(四分位距 0)vs 对照组 3 天(四分位距 1)(P = .012)。作者认为特立帕肽可能预防术后低钙血症、缩短住院时间并减少出院后钙和维生素 D 补充需求。
要点
- 甲状腺切除术后 4 小时完整 PTH 低于 10 pg/ml 的高危受试者中,特立帕肽组低钙血症 3/13 vs 对照组 11/13(P = .006)。
- 特立帕肽组相对危险度 0.26(95%CI 0.09-0.723),住院中位时间 2 天(四分位距 0)vs 对照组 3 天(四分位距 1)(P = .012)。
- 出院 1 个月时治疗组 10/13 已停用碳酸钙补充剂,对照组仅 5/13 停用;作者认为特立帕肽可能预防术后低钙血症并缩短住院。
核心结论
- 作者认为,特立帕肽可能预防甲状腺切除术后高危受试者的术后低钙血症、缩短住院时间并减少出院后钙和维生素 D 补充需求。
研究设计与样本
- 前瞻性 II 期随机开放标签试验,设于外科病房,纳入 26 例甲状腺切除术后 4 小时完整 PTH 低于 10 pg/ml 的受试者(6 例男性,20 例女性)。
- 受试者按 1:1 随机接受特立帕肽 20 mcg 每 12 小时皮下注射直至出院(治疗组)或标准临床照护(对照组)。
主要发现
- 低钙血症发生率治疗组 3/13 vs 对照组 11/13(P = .006)。
- 治疗组低钙血症风险低于对照组,相对危险度 0.26(95%CI 0.09-0.723)。
- 住院中位时间对照组 3 天(四分位距 1)vs 治疗组 2 天(四分位距 0)(P = .012)。
- 出院 1 个月时,治疗组 10/13 已停用碳酸钙补充剂,对照组仅 5/13 停用钙剂。
- 重复测量方差分析显示,两组钙补充剂在 1 个月访视时差异有统计学意义(P = .04),治疗组出院至 1 个月访视间差异亦有统计学意义(时间×分组交互作用 P = .04)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: There are no studies evaluating teriparatide for prevention of post-thyroidectomy hypocalcemia. OBJECTIVE: Our objective was to evaluate whether teriparatide can prevent postsurgical hypocalcemia and shorten the hospitalization in subjects at high risk of hypocalcemia following thyroid surgery. DESIGN: This was a prospective phase II randomized open-label trial. SETTING: This trial was set on a surgical ward. PATIENTS: Twenty-six subjects (six males, 20 females) with intact PTH lower than10 pg/ml 4 hours after thyroidectomy were included. INTERVENTION: Subjects were randomized (1:1) to receive SC administration of 20 mcg of teriparatide every 12 hours until the discharge (treatment group) or to follow standard clinical care (control group). MAIN OUTCOME MEASURE: Adjusted serum calcium, duration of hospitalization, and calcium/calcitriol supplementation were measured. RESULTS: Overall, the incidence of hypocalcemia was 3/13 in treatment group and 11/13 in the control group (P = .006). Treated patients had a lower risk of hypocalcemia than controls (relative risk, 0.26 [95% confidence interval, 0.09-0.723)]). The median duration of hospitalization was 3 days (interquartile range, 1) in control subjects and 2 days (interquartile range, 0) in treated subjects (P = .012). One month after discharge, 10/13 subjects in the treatment group had stopped calcium carbonate supplements, while only 5/13 in the control group had discontinued calcium. The ANOVA for repeated measures showed a significant difference in calcium supplements between groups at 1-month visit (P = .04) as well as a significant difference between discharge and 1-month visit in the treatment group (P for interaction time group = .04) Conclusions: Teriparatide may prevent postsurgical hypocalcemia, shorten the duration of hospitalization, and reduce the need for calcium and vitamin D supplementation after discharge in high risk subjects after thyroid surgery.
引用
- Palermo A, Mangiameli G, Tabacco G, et al. PTH(1-34) for the Primary Prevention of Postthyroidectomy Hypocalcemia: The THYPOS Trial. J Clin Endocrinol Metab. 2016. PMID: 27525532
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。